Cargando…

Identifying the Naphthalene-Based Compound 3,5-Dihydroxy 2-Napthoic Acid as a Novel Lead Compound for Designing Lactate Dehydrogenase-Specific Antibabesial Drug

Human babesiosis is caused by apicomplexan Babesia parasites, including Babesia microti, Babesia crassa, Babesia sp. MOI, Babesia divergens, Babesia duncani, and Babesia venatorum. Among them, B. microti is the most common cause of human and rodent babesiosis. Currently, no vaccine is available, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Long, Zhan, Xueyan, Liu, Qin, Sun, Yali, Li, Muxiao, Zhao, Yangnan, An, Xiaomeng, Tian, Yu, He, Lan, Zhao, Junlong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025647/
https://www.ncbi.nlm.nih.gov/pubmed/32116673
http://dx.doi.org/10.3389/fphar.2019.01663
_version_ 1783498546876514304
author Yu, Long
Zhan, Xueyan
Liu, Qin
Sun, Yali
Li, Muxiao
Zhao, Yangnan
An, Xiaomeng
Tian, Yu
He, Lan
Zhao, Junlong
author_facet Yu, Long
Zhan, Xueyan
Liu, Qin
Sun, Yali
Li, Muxiao
Zhao, Yangnan
An, Xiaomeng
Tian, Yu
He, Lan
Zhao, Junlong
author_sort Yu, Long
collection PubMed
description Human babesiosis is caused by apicomplexan Babesia parasites, including Babesia microti, Babesia crassa, Babesia sp. MOI, Babesia divergens, Babesia duncani, and Babesia venatorum. Among them, B. microti is the most common cause of human and rodent babesiosis. Currently, no vaccine is available, and drugs for the treatment have high failure rates and side effects. Due to lack of a traditional tricarboxylic acid cycle (TCA cycle) and its dominant dependence on anaerobic metabolism to produce ATP, B. microti lactate dehydrogenase (BmLDH) was assumed to play a critical role in B. microti ATP supply. Our previous study demonstrated that BmLDH is a potential drug target and Arg99 is a crucial site. Herein, a molecular docking was performed based on the crystal structure of BmLDH from a series of gossypol derivatives or structural analogs to find the potent inhibitors interacting with the residue Arg99, and three naphthalene-based compounds 2,6-naphthalenedicarboxylic acid (NDCA), 1,6-dibromo-2-hydroxynapthalene 3-carboxylic acid (DBHCA), and 3,5-dihydroxy 2-napthoic acid (DHNA) were selected for further tests. Enzyme activity inhibitory experiments show that DBHCA and DHNA inhibit recombinant BmLDH (rBmLDH) catalysis with ~109-fold and ~5,000-fold selectivity over human LDH, respectively. Surface plasmon resonance (SPR) assays demonstrate that DHNA has a lower K (D) value to BmLDH (3.766 x 10(−5) M), in contrast to a higher value for DBHCA (3.988 x 10(−8) M). A comparison of the kinetic parameters [association constant (k (a)) and dissociation constant (k (d)) values] reveals that DBHCA can bind the target faster than DHNA, while the complex of DHNA with the target dissociates slower than that of DBHCA. Both DBHCA and DHNA can inhibit the growth of B. microti in vitro with half-maximal inhibitory concentration (IC(50)) values of 84.83 and 85.65 μM, respectively. Cytotoxicity tests in vitro further indicate that DBHCA and DHNA have selectivity indexes (SI) of 2.6 and 22.1 between B. microti and Vero cells, respectively. Although the two naphthalene-based compounds only display modest inhibitory activity against both rBmLDH and the growth of B. microti, the compound DHNA features high selectivity and could serve as a novel lead compound for designing LDH-specific antibabesial drug.
format Online
Article
Text
id pubmed-7025647
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-70256472020-02-28 Identifying the Naphthalene-Based Compound 3,5-Dihydroxy 2-Napthoic Acid as a Novel Lead Compound for Designing Lactate Dehydrogenase-Specific Antibabesial Drug Yu, Long Zhan, Xueyan Liu, Qin Sun, Yali Li, Muxiao Zhao, Yangnan An, Xiaomeng Tian, Yu He, Lan Zhao, Junlong Front Pharmacol Pharmacology Human babesiosis is caused by apicomplexan Babesia parasites, including Babesia microti, Babesia crassa, Babesia sp. MOI, Babesia divergens, Babesia duncani, and Babesia venatorum. Among them, B. microti is the most common cause of human and rodent babesiosis. Currently, no vaccine is available, and drugs for the treatment have high failure rates and side effects. Due to lack of a traditional tricarboxylic acid cycle (TCA cycle) and its dominant dependence on anaerobic metabolism to produce ATP, B. microti lactate dehydrogenase (BmLDH) was assumed to play a critical role in B. microti ATP supply. Our previous study demonstrated that BmLDH is a potential drug target and Arg99 is a crucial site. Herein, a molecular docking was performed based on the crystal structure of BmLDH from a series of gossypol derivatives or structural analogs to find the potent inhibitors interacting with the residue Arg99, and three naphthalene-based compounds 2,6-naphthalenedicarboxylic acid (NDCA), 1,6-dibromo-2-hydroxynapthalene 3-carboxylic acid (DBHCA), and 3,5-dihydroxy 2-napthoic acid (DHNA) were selected for further tests. Enzyme activity inhibitory experiments show that DBHCA and DHNA inhibit recombinant BmLDH (rBmLDH) catalysis with ~109-fold and ~5,000-fold selectivity over human LDH, respectively. Surface plasmon resonance (SPR) assays demonstrate that DHNA has a lower K (D) value to BmLDH (3.766 x 10(−5) M), in contrast to a higher value for DBHCA (3.988 x 10(−8) M). A comparison of the kinetic parameters [association constant (k (a)) and dissociation constant (k (d)) values] reveals that DBHCA can bind the target faster than DHNA, while the complex of DHNA with the target dissociates slower than that of DBHCA. Both DBHCA and DHNA can inhibit the growth of B. microti in vitro with half-maximal inhibitory concentration (IC(50)) values of 84.83 and 85.65 μM, respectively. Cytotoxicity tests in vitro further indicate that DBHCA and DHNA have selectivity indexes (SI) of 2.6 and 22.1 between B. microti and Vero cells, respectively. Although the two naphthalene-based compounds only display modest inhibitory activity against both rBmLDH and the growth of B. microti, the compound DHNA features high selectivity and could serve as a novel lead compound for designing LDH-specific antibabesial drug. Frontiers Media S.A. 2020-01-30 /pmc/articles/PMC7025647/ /pubmed/32116673 http://dx.doi.org/10.3389/fphar.2019.01663 Text en Copyright © 2020 Yu, Zhan, Liu, Sun, Li, Zhao, An, Tian, He and Zhao http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Yu, Long
Zhan, Xueyan
Liu, Qin
Sun, Yali
Li, Muxiao
Zhao, Yangnan
An, Xiaomeng
Tian, Yu
He, Lan
Zhao, Junlong
Identifying the Naphthalene-Based Compound 3,5-Dihydroxy 2-Napthoic Acid as a Novel Lead Compound for Designing Lactate Dehydrogenase-Specific Antibabesial Drug
title Identifying the Naphthalene-Based Compound 3,5-Dihydroxy 2-Napthoic Acid as a Novel Lead Compound for Designing Lactate Dehydrogenase-Specific Antibabesial Drug
title_full Identifying the Naphthalene-Based Compound 3,5-Dihydroxy 2-Napthoic Acid as a Novel Lead Compound for Designing Lactate Dehydrogenase-Specific Antibabesial Drug
title_fullStr Identifying the Naphthalene-Based Compound 3,5-Dihydroxy 2-Napthoic Acid as a Novel Lead Compound for Designing Lactate Dehydrogenase-Specific Antibabesial Drug
title_full_unstemmed Identifying the Naphthalene-Based Compound 3,5-Dihydroxy 2-Napthoic Acid as a Novel Lead Compound for Designing Lactate Dehydrogenase-Specific Antibabesial Drug
title_short Identifying the Naphthalene-Based Compound 3,5-Dihydroxy 2-Napthoic Acid as a Novel Lead Compound for Designing Lactate Dehydrogenase-Specific Antibabesial Drug
title_sort identifying the naphthalene-based compound 3,5-dihydroxy 2-napthoic acid as a novel lead compound for designing lactate dehydrogenase-specific antibabesial drug
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025647/
https://www.ncbi.nlm.nih.gov/pubmed/32116673
http://dx.doi.org/10.3389/fphar.2019.01663
work_keys_str_mv AT yulong identifyingthenaphthalenebasedcompound35dihydroxy2napthoicacidasanovelleadcompoundfordesigninglactatedehydrogenasespecificantibabesialdrug
AT zhanxueyan identifyingthenaphthalenebasedcompound35dihydroxy2napthoicacidasanovelleadcompoundfordesigninglactatedehydrogenasespecificantibabesialdrug
AT liuqin identifyingthenaphthalenebasedcompound35dihydroxy2napthoicacidasanovelleadcompoundfordesigninglactatedehydrogenasespecificantibabesialdrug
AT sunyali identifyingthenaphthalenebasedcompound35dihydroxy2napthoicacidasanovelleadcompoundfordesigninglactatedehydrogenasespecificantibabesialdrug
AT limuxiao identifyingthenaphthalenebasedcompound35dihydroxy2napthoicacidasanovelleadcompoundfordesigninglactatedehydrogenasespecificantibabesialdrug
AT zhaoyangnan identifyingthenaphthalenebasedcompound35dihydroxy2napthoicacidasanovelleadcompoundfordesigninglactatedehydrogenasespecificantibabesialdrug
AT anxiaomeng identifyingthenaphthalenebasedcompound35dihydroxy2napthoicacidasanovelleadcompoundfordesigninglactatedehydrogenasespecificantibabesialdrug
AT tianyu identifyingthenaphthalenebasedcompound35dihydroxy2napthoicacidasanovelleadcompoundfordesigninglactatedehydrogenasespecificantibabesialdrug
AT helan identifyingthenaphthalenebasedcompound35dihydroxy2napthoicacidasanovelleadcompoundfordesigninglactatedehydrogenasespecificantibabesialdrug
AT zhaojunlong identifyingthenaphthalenebasedcompound35dihydroxy2napthoicacidasanovelleadcompoundfordesigninglactatedehydrogenasespecificantibabesialdrug